Gene therapy involves the introduction of new genes into cells, to restore or add gene expression, for the purpose of treating disease. Most commonly a mutated gene is replaced with DNA encoding a functional copy. Alternatively DNA encoding a therapeutic protein drug may be introduced.Featured...
You can also make a donation by PayPal and support the Gene Therapy Net website. Most Popular Items Breaking Gene Therapy News Diseases Treated by Gene Therapy Types of Gene Therapy Adeno-Associated Viral Vectors Glossary of Gene Therapy Terms ...
A one-time gene-editing therapy restored motor function and prolonged lifespan in mice, spurring further research to refine and optimize the approach for future clinical use. Karen O’Leary News & Views | 16 February 2023 CRISPR gene-editing therapies for hypertrophic cardiomyopathy Pre-symptoma...
Brochure Solutions Products News & events Resources & support Connect every phase of your cell and gene therapy journey We connect you to end-to-end cell and gene therapy solutions that help you deliver life-changing therapies. Our mission is to provide you with connections to help you reach ...
By the IMARC group, the global gene therapy reached USD 5.8 Billion in 2024, projected to reach USD 17.9 Billion by 2033, exhibiting a growth rate (CAGR) of 13.3% during 2025-2033.
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found. The University of Bristol-led study, published in Molecular Therapy, reveals how age ... Feb 10, 2025 ...
News & Views23 Aug 2024 Nature Biotechnology P: 1-3 Andrew C. G. Porter (1955–2023) Rafael J. Yáñez-Muñoz Jane E. Itzhaki Comments & Opinion29 Jul 2024 Gene Therapy Volume: 31, P: 437-438 RNA editing with CRISPR Petra Gross Research Highlights13 Jun 2024 Nature Genetic...
Gene Therapy News.Reports on developments related to gene therapy as of October 1997. Formation of gene therapy company Cardiogene; CytoTherapeutics' acquisition of StemCells; Collaboration between Gene Medicine and Boehringer Mannheim.MichaelAdamEBSCO_AspGene Therapy...
s experimental Rett syndrome gene therapy has died. Neurogene disclosed the death in a regulatory filing after the market close Thursday. The company said the FDA is permitting the Phase 1/2 study to continue with the low dose of the therapy, code-named NGN-401. Neurogene added that it ...
Data from a phase 2 pharmacodynamic study of ABBV-RGX-314 gene therapy were presented at ASRS 2024. An investigational single-administration gene therapy that delivers a transgene for a soluble anti-vascular endothelial growth factor (VEGF) Fab, the wet AMD therapy is in currently being examined ...